Joint venture contract with Zydus Cadila to be amended for the production of active pharmaceutical ingredients (API) Transfer of chemical production from facilities in Singen (Germany) and Linz (Austria) to India until 2011 Singen and Linz will focus on pharmaceutical production Nycomed and Cadila Healthcare have signed a letter agreement with the intent to amend their existing joint venture agreement to include the chemical production of active pharmaceutical ingredients (APIs) by the joint venture company Zydus Nycomed in India......

Total net turnover increases by 3.0% to € 3,497.4 million 31.0% increase in adjusted EBITDA Instanyl™ filed for European approval Own Pantoprazole generic as response to US at-risk launch Major progress in US out-licensing strategy Acquisition of Bradley Pharmaceuticals successfully closed The financial results reported in this press release are related to Nycomed S......

Nycomed creates a leading specialty pharmaceutical player in dermatology Enhanced platform for in-licensing and co-promotion of dermatology products Combined US dermatology sales of $450 million Today, Nycomed successfully completed the acquisition of Bradley Pharmaceuticals, a company focused on niche therapeutic markets in the United States......